Amgen Inc

Quantli Newsdesk

· 10 days ago

Amgen reported second-quarter revenue of $10.1 billion, up 10% year-over-year, driven by strong sales of cholesterol drug Repatha (+37%) and bone drug Evenity (+38%). Adjusted earnings per share rose 4% to $6.29, beating analyst estimates of $5.62. The company raised its full-year revenue outlook to $38.2 billion to $39.4 billion and discontinued early-stage obesity candidate AMG 513.

10-K

Quantli Newsdesk

· 4 months ago

Amgen reported 10% revenue growth to $36.8 billion driven by 13% volume growth, offset by 3% net price declines. Operating income surged 25% to $9.1 billion as prior-year Horizon acquisition costs rolled off, but the company faces accelerating biosimilar erosion for Prolia/XGEVA and Medicare price setting for ENBREL (2026) and Otezla (2027).